Search

Your search keyword '"Carlo Morasso"' showing total 2 results
Start Over Author "Carlo Morasso" Journal molecules
2 results on '"Carlo Morasso"'

1. Curcumin Formulations and Trials: What’s New in Neurological Diseases

Author

Stella Gagliardi, Carlo Morasso, Polychronis Stivaktakis, Cecilia Pandini, Veronica Tinelli, Aristides Tsatsakis, Davide Prosperi, Miriam Hickey, Fabio Corsi, and Cristina Cereda

Subjects
curcumin, neurological diseases, nanoformulation, clinical trials, Organic chemistry, QD241-441
Abstract

Curcumin’s pharmacological properties and its possible benefits for neurological diseases and dementia have been much debated. In vitro experiments show that curcumin modulates several key physiological pathways of importance for neurology. However, in vivo studies have not always matched expectations. Thus, improved formulations of curcumin are emerging as powerful tools in overcoming the bioavailability and stability limitations of curcumin. New studies in animal models and recent double-blinded, placebo-controlled clinical trials using some of these new formulations are finally beginning to show that curcumin could be used for the treatment of cognitive decline. Ultimately, this work could ease the burden caused by a group of diseases that are becoming a global emergency because of the unprecedented growth in the number of people aged 65 and over worldwide. In this review, we discuss curcumin’s main mechanisms of action and also data from in vivo experiments on the effects of curcumin on cognitive decline.

Published
2020
Full Text
View/download PDF

2. Curcumin Formulations and Trials: What’s New in Neurological Diseases

Author

Carlo Morasso, Stella Gagliardi, Polychronis Stivaktakis, Davide Prosperi, Cecilia Pandini, Cristina Cereda, Aristides M. Tsatsakis, Miriam A Hickey, Veronica Tinelli, Fabio Corsi, Gagliardi, S, Morasso, C, Stivaktakis, P, Pandini, C, Tinelli, V, Tsatsakis, A, Prosperi, D, Hickey, M, Corsi, F, and Cereda, C

Subjects
Drug Compounding, Pharmaceutical Science, Review, Bioinformatics, Analytical Chemistry, lcsh:QD241-441, 03 medical and health sciences, chemistry.chemical_compound, Cognition, 0302 clinical medicine, lcsh:Organic chemistry, Drug Discovery, Animals, Humans, Medicine, Dementia, curcumin, neurological disease, Physical and Theoretical Chemistry, Cognitive decline, 030304 developmental biology, Clinical Trials as Topic, 0303 health sciences, clinical trials, business.industry, Organic Chemistry, nanoformulation, medicine.disease, Clinical trial, Disease Models, Animal, chemistry, Chemistry (miscellaneous), Curcumin, Molecular Medicine, Nervous System Diseases, business, 030217 neurology & neurosurgery, neurological diseases
Abstract

Curcumin’s pharmacological properties and its possible benefits for neurological diseases and dementia have been much debated. In vitro experiments show that curcumin modulates several key physiological pathways of importance for neurology. However, in vivo studies have not always matched expectations. Thus, improved formulations of curcumin are emerging as powerful tools in overcoming the bioavailability and stability limitations of curcumin. New studies in animal models and recent double-blinded, placebo-controlled clinical trials using some of these new formulations are finally beginning to show that curcumin could be used for the treatment of cognitive decline. Ultimately, this work could ease the burden caused by a group of diseases that are becoming a global emergency because of the unprecedented growth in the number of people aged 65 and over worldwide. In this review, we discuss curcumin’s main mechanisms of action and also data from in vivo experiments on the effects of curcumin on cognitive decline.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results